Sign In
Buy DMAC
$6.34
-0.170 (-2.61%)
At Close: Jul 31, 2026
Hedge Funds Getting Interested In DiaMedica Therapeutics Inc. (DMAC)
12:16am, Thursday, 11'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filing
DiaMedica Therapeutics to Present at the 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020
08:42pm, Tuesday, 19'th May 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 17th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, May 27, 20
DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study
08:41pm, Wednesday, 13'th May 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for neurological disorders and chronic kidney disease, announced today that DM199, a
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today announced positive t
DiaMedica Therapeutics to Report First Quarter 2020 Financial Results and Provide a Business Update May 14, 2020
08:30pm, Thursday, 07'th May 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2020 financial results will be released after the markets close on Wednesday, May 13th. DiaMedica will host a live con
DiaMedica Therapeutics to Present Research at National Kidney Foundation 2020 Spring Clinical Meetings Live Virtual Conference
01:12pm, Thursday, 26'th Mar 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that the Company will be presenting a poster titled "Open-label Study of the Pharmacokinetics, Safet
DiaMedica Therapeutics, Inc. to Host Earnings Call
10:00am, Tuesday, 24'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 24, 202
DiaMedica Therapeutics Announces 2019 Financial Results and Provides Business Update
08:35pm, Monday, 23'rd Mar 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today provided a business
The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus
06:25pm, Sunday, 22'nd Mar 2020
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Biotech stocks went on a roller coaster ride in the week
DiaMedica Therapeutics to Report Fourth Quarter 2019 Financials and Provide a Business Update March 24, 2020
12:10pm, Tuesday, 17'th Mar 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its fourth quarter 2019 financial results will be released after the markets close on Monday, March 23rd. DiaMedica will host a live con
DiaMedica Therapeutics to Participate at 32nd Annual ROTH Conference on March 15-17, 2020
12:10pm, Monday, 09'th Mar 2020
DiaMedica Therapeutics to Participate at 32nd Annual ROTH Conference on March 15-17, 2020
DiaMedica Therapeutics Announces Closing of $8.5 Million Public Offering of Common Shares
09:35pm, Thursday, 13'th Feb 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced the closing of its previously announced underwritten public offering of an aggregate of 2,125,000 sh
DiaMedica Announces Pricing of Public Offering of Common Shares
12:15pm, Tuesday, 11'th Feb 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of an underwritten registered public offering of 2,125,000 of its common shares at a pri
Hedge Funds Have Never Been More Bullish On DiaMedica Therapeutics Inc. (DMAC)
07:32pm, Monday, 23'rd Dec 2019
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Se
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney
